Your browser doesn't support javascript.
loading
Human model of primary carnitine deficiency cardiomyopathy reveals ferroptosis as a novel mechanism.
Loos, Malte; Klampe, Birgit; Schulze, Thomas; Yin, Xiaoke; Theofilatos, Konstantinos; Ulmer, Bärbel Maria; Schulz, Carl; Behrens, Charlotta S; van Bergen, Tessa Diana; Adami, Eleonora; Maatz, Henrike; Schweizer, Michaela; Brodesser, Susanne; Skryabin, Boris V; Rozhdestvensky, Timofey S; Bodbin, Sara; Stathopoulou, Konstantina; Christ, Torsten; Denning, Chris; Hübner, Norbert; Mayr, Manuel; Cuello, Friederike; Eschenhagen, Thomas; Hansen, Arne.
Afiliação
  • Loos M; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany. Electronic address: m.loos@uke.de.
  • Klampe B; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany.
  • Schulze T; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany.
  • Yin X; King's British Heart Foundation Centre of Research Excellence, King's College London, London, UK.
  • Theofilatos K; King's British Heart Foundation Centre of Research Excellence, King's College London, London, UK.
  • Ulmer BM; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Schulz C; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Behrens CS; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • van Bergen TD; Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
  • Adami E; Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
  • Maatz H; Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
  • Schweizer M; Electron Microscopy Unit, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Brodesser S; Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Faculty of Medicine and University Hospital of Cologne, 50931 Cologne, Germany.
  • Skryabin BV; Transgenic animal and genetic engineering Models (TRAM), Faculty of Medicine of the Westfalian Wilhelms-University, 48149 Muenster, Germany.
  • Rozhdestvensky TS; Transgenic animal and genetic engineering Models (TRAM), Faculty of Medicine of the Westfalian Wilhelms-University, 48149 Muenster, Germany.
  • Bodbin S; Division of Cancer & Stem Cells, Biodiscovery Institute, University of Nottingham, NG7 2RD Nottingham, UK.
  • Stathopoulou K; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Christ T; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Denning C; Division of Cancer & Stem Cells, Biodiscovery Institute, University of Nottingham, NG7 2RD Nottingham, UK.
  • Hübner N; Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 13347 Berlin, Germany; Charité-Universitätsmedizin, 10117 Berlin, Germany.
  • Mayr M; King's British Heart Foundation Centre of Research Excellence, King's College London, London, UK.
  • Cuello F; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Eschenhagen T; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany.
  • Hansen A; University Medical Center Hamburg-Eppendorf, Department of Experimental Pharmacology and Toxicology, 20246 Hamburg, Germany; German Center for Heart Research (DZHK), Partner site Hamburg/Lübeck/Kiel, 20246 Hamburg, Germany. Electronic address: ar.hansen@uke.de.
Stem Cell Reports ; 18(11): 2123-2137, 2023 11 14.
Article em En | MEDLINE | ID: mdl-37802072
ABSTRACT
Primary carnitine deficiency (PCD) is an autosomal recessive monogenic disorder caused by mutations in SLC22A5. This gene encodes for OCTN2, which transports the essential metabolite carnitine into the cell. PCD patients suffer from muscular weakness and dilated cardiomyopathy. Two OCTN2-defective human induced pluripotent stem cell lines were generated, carrying a full OCTN2 knockout and a homozygous OCTN2 (N32S) loss-of-function mutation. OCTN2-defective genotypes showed lower force development and resting length in engineered heart tissue format compared with isogenic control. Force was sensitive to fatty acid-based media and associated with lipid accumulation, mitochondrial alteration, higher glucose uptake, and metabolic remodeling, replicating findings in animal models. The concordant results of OCTN2 (N32S) and -knockout emphasizes the relevance of OCTN2 for these findings. Importantly, genome-wide analysis and pharmacological inhibitor experiments identified ferroptosis, an iron- and lipid-dependent cell death pathway associated with fibroblast activation as a novel PCD cardiomyopathy disease mechanism.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Ferroptose / Cardiomiopatias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Stem Cell Reports Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Ferroptose / Cardiomiopatias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Stem Cell Reports Ano de publicação: 2023 Tipo de documento: Article